+97.9%
VICI vs GSK
+100.8%
-2.9%
-60.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | +0.2% | -0.4% | -0.3% |
| 7D | -1.6% | -3.6% | +2.0% | 0.0% |
| 30D | -3.3% | -5.9% | +2.6% | -0.9% |
| 3M | -8.5% | -4.3% | -4.3% | -7.0% |
| 6M | -11.7% | -10.8% | -0.9% | -7.7% |
| YTD | -7.4% | +1.8% | -9.1% | -9.0% |
| 1Y | -19.0% | +23.5% | -42.4% | -27.6% |
| 3Y | -3.9% | +49.5% | -53.5% | -24.8% |
| 5Y | +10.6% | +49.7% | -39.0% | -16.8% |
| All | +97.9% | +100.8% | -2.9% | +34.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling